Reference and Ghost Proteins Identification in Rat C6 Glioma Extracellular Vesicles

Murgoci, Adriana-Natalia; Cardon, Tristan; Aboulouard, Soulaimane; Duhamel, Marie; Fournier, Isabelle; Cizkova, Dasa

doi:10.1016/j.isci.2020.101045

Cited by 20 publications

(11 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ARCN1 protein is mainly expressed in inflamed tissues 46 . Another BPI-induced gene, VPS37b, is recently reported as a surface protein on the glioma-derived exosomes 47 . It is possible that the BPI-ARCN1 axis or BPI-VPS37b axis in T cells facilitates exosome formation, leading to inflammatory exosome infiltration into target tissues.…”

Section: Discussionmentioning

confidence: 99%

BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus

Chuang

Chen

et al. 2021

Theranostics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus

Chuang

Chen

et al. 2021

Theranostics

View full text Add to dashboard Cite

“…170 alternative proteins (AltProts) were found significantly variable in the three groups identified above. If the function of these AltProts are still poorly understood, it has been shown that they can have a role in regulation of transcription and can also be present in extracellular vesicles (77). Finally, more than 50% of the AltProts identified in the present study come from the translation of ncRNAs transcribed from pseudogenes.…”

Section: Discussionmentioning

confidence: 99%

Overall patient’s survival of glioblastoma associated to molecular markers: a pan-proteomic prospective study

Drelich

Duhamel

Wisztorski

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

SUMMARYMolecular heterogeneities are a key feature of glioblastoma (GBM) pathology impeding patient’s stratification and leading to high discrepancies between patients mean survivals. Here, we established a molecular classification of GBM tumors using a pan-proteomic analysis. Then, we identified, from our proteomic data, 2 clusters of biomarkers associated with good or bad patient survival from 46 IDH wild-type GBMs. Three molecular groups have been identified and associated with systemic biology analyses. Group A tumors exhibit neurogenesis characteristics and tumorigenesis. Group B shows a strong immune cell signature and express poor prognosis markers while group C tumors are characterized by an anti-viral signature and tumor growth proteins. 124 proteins were found statistically different based on patient’s survival times, of which 10 are issued from alternative AltORF or non-coding RNA. After statistical analysis, a panel of markers associated to higher survival (PPP1R12A, RPS14, HSPD1 and LASP1) and another panel associated to lower survival (ALCAM, ANXA11, MAOB, IP_652563 and IGHM) has been validated by immunofluorescence. Taken together, our data will guide GBM prognosis and help to improve the current GBM classification by stratifying the patients and may open new opportunities for therapeutic development.SignificanceGlioblastoma are very heterogeneous tumors with median survivals usually inferior to 20 months. We conducted a pan-proteomics analysis of glioblastoma (GBM) in order to stratify GBM based on the molecular contained. Forty-six GBM cases were classified into three groups where proteins are involved in specific pathways i.e. the first group has a neurogenesis signature and is associated with a better prognosis while the second group of patients has an immune profile with a bad prognosis. The third group is more associated to tumorigenesis. We correlated these results with the TCGA data. Finally, we have identified 28 new prognostic markers of GBM and from these 28, a panel of 4 higher and 5 lower survival markers were validated. With these 9 markers in hand, now pathologist can stratify GBM patients and can guide the therapeutic decision.HighlightsA novel stratification of glioblastoma based on mass spectrometry was established.Three groups with different molecular features and survival were identified.This new classification could improve prognostication and may help therapeutic options.8 prognosis markers for oncologist therapeutic decision have been validated.

show abstract

“…In the last years, several studies have focused on the use of EVs as biomarkers to obtain information about the presence and/or the molecular evolution of neoplastic diseases (Le Rhun et al, 2020 ; Murgoci et al, 2020a ). In addition, the use of EVs for glioma therapy has been explored.…”

Section: Possible Therapeutic Strategies For Cns Disorders Based On Ementioning

confidence: 99%

Glia-Derived Extracellular Vesicles: Role in Central Nervous System Communication in Health and Disease

Pistono

Bister

Stanová

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Glial cells are crucial for the maintenance of correct neuronal functionality in a physiological state and intervene to restore the equilibrium when environmental or pathological conditions challenge central nervous system homeostasis. The communication between glial cells and neurons is essential and extracellular vesicles (EVs) take part in this function by transporting a plethora of molecules with the capacity to influence the function of the recipient cells. EVs, including exosomes and microvesicles, are a heterogeneous group of biogenetically distinct double membrane-enclosed vesicles. Once released from the cell, these two types of vesicles are difficult to discern, thus we will call them with the general term of EVs. This review is focused on the EVs secreted by astrocytes, oligodendrocytes and microglia, aiming to shed light on their influence on neurons and on the overall homeostasis of the central nervous system functions. We collect evidence on neuroprotective and homeostatic effects of glial EVs, including neuronal plasticity. On the other hand, current knowledge of the detrimental effects of the EVs in pathological conditions is addressed. Finally, we propose directions for future studies and we evaluate the potential of EVs as a therapeutic treatment for neurological disorders.

show abstract

Reference and Ghost Proteins Identification in Rat C6 Glioma Extracellular Vesicles

Cited by 20 publications

References 36 publications

BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus

BPI overexpression suppresses Treg differentiation and induces exosome-mediated inflammation in systemic lupus erythematosus

Overall patient’s survival of glioblastoma associated to molecular markers: a pan-proteomic prospective study

Glia-Derived Extracellular Vesicles: Role in Central Nervous System Communication in Health and Disease

Contact Info

Product

Resources

About